D-1740-2019 Class II Terminated

Recalled by US Pharmaceuticals Inc. — Belleville, NJ

FDA drug recall D-1740-2019 was initiated by US Pharmaceuticals Inc. on Jul 11, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process. The recall status is terminated (terminated Jun 25, 2020). Affected quantity: 147 cases.

Recall details

Product Type
Drugs
Report Date
Aug 21, 2019
Initiation Date
Jul 11, 2019
Termination Date
Jun 25, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
147 cases

Product description

Wonder Freeze Pain Releiving Gel with ILEX, Menthol 5%, packaged in a) 3 OZ /85 g (UPC 0 99528 35903 5); b) 4 OZ / 113 g (UPC 0 99528 31504 8); c) 16 OZ / 454 g (UPC 0 99528 31516 1); Manufactured For: Wonder Laboratories, 115 S.C.T. Ct., White House TN. 37188.

Reason for recall

CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot # a) 21J18, EXP 07/2021 b) 42H18, EXP 06/2021; c) 32H18, EXP 6/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1740-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1740-2019. Report a data issue: hello@regdatalab.com.